Browsing by Author "emine bihter eniseler"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Timik Metastaz ile Prezente Olan Meme Karsinomu: Bir Olgu Sunumu
    (2023) emine bihter eniseler; ferhat ekinci; FATMA CAN; ATIKE PINAR ERDOGAN; Gamze GOKSEL
    Timus, superior ve anterior mediastinumda yerleşik primer lenfoid bir organdır. Anterior mediastinal tümörlerin neredeyse tamamını timik tümörler oluşturmaktadır. Timomalar, erişkinlerde timusun en sık görülen tümörleri olmakla birlikte, timusa bir tümörün metastazı oldukça nadirdir. Timustaki yer kaplayan oluşumların tanısı sıklıkla klinik ve radyolojik bulgular ile konur ve histopatolojik inceleme ile kesinleşmektedir. Bu yazıda mastektomi sonrası 9. yılda soliter timus metastazı gözlenen meme kanseri tanılı bir olgu sunulmaktadır.
  • No Thumbnail Available
    Item
    Real-Life Data of Neoadjuvant Chemotherapy in Breast Cancer: Aegean Region Experience
    (2023) ferhat ekinci; Ahmet Özveren; emine bihter eniseler; Bilgin Demir; Mustafa Şahbazlar; ATIKE PINAR ERDOGAN
    Objective: The use of neoadjuvant chemotherapy (NACT) in breast cancer is increasing. However the management of locally advanced breast cancer differs due to the approach of the center to which the patient applied and the approach of the following physician. From this point of view, we aimed to evaluate the real life data of our region. Methods: The study included 106 patients treated with NACT in the medical oncology clinic of two different university hospitals. Association between clinicopathological features and pathological complete response (pCR) were analyzed. Results: The pCR rate was higher in patients with negative hormone receptors and this difference was statistically significant (p:0.000). The rate of obtaining pCR increased as the NACT duration increased, and this increase was statistically significant. The mean NACT duration applied to the patients with pCR was 5.48 ± 0.22 months, and the mean NACT duration for those who could not obtain pCR was 5.01 ± 0.1 months (p:0.041). The recurrence rate of patients with pCR was 11.1%, while the recurrence rate of patients who could not obtain pCR was 31.6% (p:0.04). Conclusion: Pathological response to chemotherapy is an important factor in determining prognosis. There appears to be a need for new biomarkers that allow the prediction of pCR and long-term outcomes.